Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 (SURVODUTIDE) in overweight or obesity with type 2 diabetes mellitus
2022-502531-18-00Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in obesity and type 2 diabetes mellitus (T2DM) comparing SURVODUTIDE with Placebo (2 arms). Primary endpoints: Percentage change in body weight from baseline to Week 76 and Achievement of body weight reduction ≥5% from baseline to Week 76. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-502531-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502531-18-00.